Literature DB >> 14577345

[Activity of cephems and carbapenems against clinically isolated Mycobacterium abscessus].

Kunihiko Ito1, Kenichi Hashimoto, Hideo Ogata.   

Abstract

To screen effective useful drugs for disease due to M. abscessus, we determined MIC of 3 cephems [ceftazidime (CAZ), cefoxitin (CFX), flomoxef (FMOX)] and 3 carbapenems [imipenem (IPM), panipenem (PAPM), meropenem (MEPM)] for 8 strains of clinically isolated M. abscessus by micro-dilution method using MGIT system. In all the 8 strains, MICs of CAZ are higher than 32 micrograms/ml. MIC50, MIC90, MIC range of CFX are 32 micrograms/ml, > 32 micrograms/ml and 16- > 32 micrograms/ml respectively, and for FMOX, 16 micrograms/ml, 32 micrograms/ml and 16-32 micrograms/ml; for IPM, 8 micrograms/ml, 16 micrograms/ml and 8-16 micrograms/ml; for PAPM, 4 micrograms/ml, 16 micrograms/ml and 4-16 micrograms/ml; for MEPM, 8 micrograms/ml, 16 micrograms/ml and 8-16 micrograms/ml. From this study, it is concluded that FMOX, IPM, PAPM and MEPM can be clinically useful drugs in the treatment of the disease due to M. abscessus.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14577345

Source DB:  PubMed          Journal:  Kekkaku        ISSN: 0022-9776


  2 in total

1.  Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus.

Authors:  Amit Kaushik; Chhavi Gupta; Stefanie Fisher; Elizabeth Story-Roller; Christos Galanis; Nicole Parrish; Gyanu Lamichhane
Journal:  Future Microbiol       Date:  2017-02-16       Impact factor: 3.165

Review 2.  Mycobacterium abscessus and β-Lactams: Emerging Insights and Potential Opportunities.

Authors:  Elizabeth Story-Roller; Emily C Maggioncalda; Keira A Cohen; Gyanu Lamichhane
Journal:  Front Microbiol       Date:  2018-09-25       Impact factor: 5.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.